一图解码:“生长发育第一股”维升药业过港交所聆讯 亏损持续收窄

IPO解码
12 Feb

历经四次递表后,维升药业通过了港交所聆讯,并于2月9日更新了聆讯后招股书;由摩根士丹利和杰弗瑞担任联席保荐人。维升药业于2018年11月成立,是一家处于研发后期、产品接近商业化的生物制药公司,专注于在中国(包括香港、澳门及台湾)提供特定内分泌疾病的治疗方案。据披露,维升药业拥有一款核心产品——隆培促生长素(lonapegsomatropin),自其合作伙伴及控股股东之一Ascendis ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10